Ironwood Pharmaceuticals (IRWD) FCF Margin (2010 - 2026)

Ironwood Pharmaceuticals has disclosed FCF Margin across 17 years of filings, most recently posting 51.55% for Q2 2026.

• In Q2 2026, FCF Margin rose 6923.0% year-over-year to 51.55%; the TTM figure through Jun 2026 stood at 47.66% (up 3796.0% YoY), while the FY2025 annual figure was 42.89%, up 1346.0% from the prior year.
• FCF Margin came in at 51.55% for Q2 2026 at Ironwood Pharmaceuticals, up from 4.81% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 156.31% in Q4 2025 to a low of 17.68% in Q2 2025.
• Average FCF Margin over 5 years is 46.66%, with a median of 43.7% recorded in 2025.
• The largest YoY upside for FCF Margin was 13951 bps in 2025 against a maximum downside of 5307 bps in 2025.
• Over 5 years, FCF Margin stood at 73.89% in 2022, then tumbled by 59 bps to 30.3% in 2023, then slumped by 45 bps to 16.8% in 2024, then surged by 830 bps to 156.31% in 2025, then tumbled by 67 bps to 51.55% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 51.55% in Q2 2026, 4.81% in Q1 2026, and 156.31% in Q4 2025.